Execution drift: Why pharmaceutical go-to-market falls short of its own strategy

Pharmaceutical organisations rarely struggle to write strategy. They struggle to protect it. Global brand teams define ambition precisely. Segmentation models are refined. Launch plans are comprehensive. CRM systems are configured to drive execution discipline. Advanced analytics promise visibility and control.

Capability is not the constraint.

Yet, commercial performance remains uneven. Launch trajectories diverge across comparable markets. Priority segments underdeliver against forecast. Activity levels rise without proportional impact. Leadership teams sense misalignment, but struggle to isolate its source.

The issue is rarely intelligence, effort, or technology.

It is structural drift.

When strategy stops reinforcing itself

Execution drift occurs when strategy, targeting, metrics, incentives, and behaviour gradually stop reinforcing one another. Each element may function adequately in isolation. Misalignment emerges in the connections between them.

Target lists broaden under quarterly pressure. KPIs multiply in pursuit of visibility. Incentive weightings shift subtly towards aggregate volume. CRM workflows capture activity, but do not enforce prioritisation. Local adaptation reshapes global intent. Reporting expands to monitor variance, but fragments signal clarity.

None of these adjustments appears material on its own. Collectively, they dilute direction.

Most organisations respond by adding structure: more dashboards, tighter governance, increased reporting cadence. Leverage declines.

Drift rarely produces visible failure. Dashboards still populate. Field teams remain active. Forecast updates continue. The system appears operational. However, beneath the surface, friction accumulates. Resource intensity diffuses. Segment penetration lags. Variability widens.

The cost is not collapse. It is cumulative underperformance against strategic ambition.

Why drift is the default

Heightened launch scrutiny and rising performance expectations place sustained pressure on commercial systems. Global strategy must translate into local execution across diverse access environments, pricing conditions, and competitive dynamics. At the same time, portfolio priorities shift and data sources vary in definition and reliability.

Each force is legitimate. Together, they create strain.

Global strategy may be clear. Segmentation logic and priority cohorts may be well articulated. Over time, as that intent moves through local interpretation, quarterly pressure and evolving market realities, incremental adaptation begins.

A segment definition widens slightly to reflect access constraints. Targeting logic expands to protect near-term revenue. Incentives tilt toward total growth. Additional KPIs are layered into reporting to increase visibility.

Each decision is defensible. Collectively, they loosen alignment.

Over time, behaviour becomes shaped more by what is measured and rewarded than by what was originally prioritised. Dashboards emphasise activity as prominently as strategic penetration. Incentives reinforce breadth, rather than depth. Leadership conversations centre on short-term variance recovery, rather than strategic reinforcement.

The organisation remains busy. Focus erodes.

Since revenue may still grow, underlying friction is often misinterpreted as normal market fluctuation. The result is a system that works harder to generate the same return.

Drift is cumulative. It rarely creates immediate crisis. It gradually reduces leverage quarter by quarter. The cost often remains invisible until ambition begins to slip.

The economic cost of drift

Execution drift rarely appears as failure. It appears as drag.

Commercial efficiency erodes as targeting expands beyond priority segments. Resource intensity per high-value account declines. Engagement depth weakens. Activity increases, but marginal return per interaction falls.

Segment under-penetration follows. High-value cohorts do not achieve expected depth. Influence within priority accounts builds more slowly than forecast. Adoption patterns flatten, rather than concentrate.

Launch environments are particularly vulnerable. Early volatility intensifies scrutiny. Markets expand engagement beyond defined high-value cohorts to accelerate uptake. Incentives reward breadth. Reporting highlights total sales, rather than cohort-specific penetration. The intended market shape becomes blurred.

Mid-cycle correction is expensive. It requires recalibrating targeting, incentives, and reporting simultaneously. Prevention would have required protecting alignment earlier.

Measurement inconsistency adds further friction. When sales figures vary slightly across systems and segment definitions are not synchronised, confidence declines. Performance discussions become defensive, rather than directional. Decision-making slows.

The most significant cost is opportunity foregone. In competitive therapeutic areas, coherent systems enable decisive movement. Focused targeting accelerates influence. Clear metrics enable confident investment. Aligned incentives reinforce depth.

When coherence weakens, opportunity windows narrow before alignment is restored.

Execution drift functions as a hidden tax. Each misalignment adds friction. Each friction point compounds.

Commercial coherence

If drift describes the failure state, coherence describes the discipline that prevents it.

Structured planning frameworks provide intellectual order. They clarify how organisations should move from situation analysis to objectives, strategy, tactics, and control. But planning logic alone does not guarantee operational alignment.

Commercial coherence refers to the strength of reinforcement across the operating system.

It describes the degree to which strategic intent is embedded across targeting decisions, tactical design, incentive structures, reporting hierarchies, and behavioural signals so that each element strengthens, rather than weakens the others.

In coherent systems, commercial activity does not simply occur alongside strategy. It is shaped by it.

The go-to-market chain is best understood not as a linear sequence, but as a closed loop. Situation understanding informs objective selection. Objectives define trade-offs. Strategy determines where to compete. Targeting operationalises that choice at account level. Tactics reflect prioritisation. Execution reinforces behavioural alignment. Measurement reconnects performance outcomes to original intent.

When coherence is strong, this loop compounds leverage. Variability between comparable markets narrows. Tactical decisions reinforce strategic differentiation. Incentives signal depth where depth is required. Metrics clarify, rather than fragment.

When coherence weakens, misalignment propagates. A modest broadening of objectives leads to widened targeting. Tactical breadth increases. Resource intensity per priority segment declines. Incentives signal aggregate growth. Behaviour adjusts accordingly. Leadership responds by adding measurement layers to regain control. The system grows more complex while becoming less aligned.

What appears as performance volatility may in fact be system fragility.

Commercial coherence can therefore be understood as an operating discipline, rather than a planning philosophy.

In coherent systems, reinforcement is visible. Leaders can articulate not only the strategic choice, but the mechanisms that protect it. Target lists reflect declared prioritisation. Incentives reinforce depth where depth is required. Metric hierarchies distinguish strategic penetration from operational variance. Tactical intensity varies deliberately by segment value, rather than uniformly across accounts.

In incoherent systems, the reverse pattern emerges. Target expansion occurs without formal decision. Incentive structures adjust incrementally in response to volatility. Reporting layers multiply. Leadership attention shifts from reinforcing trade-offs to reconciling variance. The system absorbs complexity without increasing leverage.

The distinction is subtle, but material. Coherence does not eliminate volatility. It ensures that volatility does not rewrite strategy.

Organisations that sustain coherence demonstrate three characteristics. First, prioritisation remains explicit even under pressure. Second, reinforcement mechanisms are periodically examined, rather than assumed to persist. Third, adaptation occurs through deliberate recalibration, rather than incremental expansion.

This discipline is rarely dramatic. It is quiet, systemic, and cumulative. Over time, however, it separates organisations that compound leverage from those that gradually diffuse it.

Diagnosing drift in practice

Recognising execution drift is not sufficient. Leadership teams require a disciplined way to examine whether strategic intent remains embedded in the system.

The earliest signals often appear in concentration patterns. Are defined priority accounts still receiving disproportionate resource relative to their declared value? Has targeting widened incrementally without explicit strategic decision? When penetration depth within priority segments is compared with total coverage growth, does the pattern reflect intention or drift?

Metric hierarchy is equally revealing. Do dashboards clearly prioritise strategic penetration indicators, or present operational activity metrics with equal prominence? Has reporting complexity increased faster than signal clarity? Are leadership conversations focused on reinforcing intent, or primarily on short-term variance recovery?

Incentive architecture provides another diagnostic lens. When incentive weighting subtly shifts in response to volatility, does it continue to reinforce declared prioritisation, or does it reward aggregate activity? Behaviour will always follow signal.

Importantly, coherence rarely fails uniformly. Strategy may remain clear while targeting discipline weakens. Analytics may be sophisticated while incentives misalign. The pattern of misalignment matters more than any single metric.

Without structured examination, organisations tend to respond to volatility by adding complexity. Additional dashboards are introduced. Governance layers expand. New KPIs are layered into reporting cycles. These responses create an illusion of control while increasing internal friction.

With disciplined assessment, leadership can remove, rather than add, complexity. Target lists are recalibrated intentionally. Metric hierarchies are simplified. Incentive structures are aligned to strategic depth, rather than breadth. Reinforcement is examined at the earliest visible distortion point, rather than after performance deterioration becomes visible.

Drift is not prevented by intention alone. It is prevented by deliberate reinforcement review.

From drift to discipline

Pharmaceutical organisations do not drift because they lack intelligence or ambition. They drift because complexity accumulates faster than reinforcement is examined.

Coherence must therefore be protected deliberately.

Strategic trade-offs must remain visible beyond planning cycles. Which segments justify disproportionate investment? Which accounts warrant depth over breadth? Where should resource intensity remain protected under volatility?

Incentives must be treated as system levers, rather than short-term reaction tools. Metric hierarchies must clarify, rather than obscure. Leadership cadence must protect alignment before drift compounds.

Adaptation is necessary. Markets evolve. Access conditions shift. Competitive intensity fluctuates. However, adaptation should occur through deliberate recalibration, rather than incremental expansion.

In systems governed by expansion, complexity accumulates without leverage. In systems governed by discipline, complexity is absorbed without distortion.

Execution drift is natural. Sustained coherence is deliberate.

The most important question for commercial leaders is not whether strategy is sound. It is whether the operating system is amplifying or diluting it.

Performance does not improve because organisations add activity. It improves when strategic intent remains embedded and reinforced across the system.

Strategy does not fail in the boardroom.

It fails in the system.

About the author

Paul O’Nions, founder & managing director of GTMx Consulting, brings over 20 years of pharmaceutical industry experience in commercial strategy, business intelligence, and go-to-market transformation. He advises organisations on segmentation, targeting, CRM strategy, analytics integration, and launch preparedness, with a focus on strengthening alignment between strategic intent and execution. O’Nions has served on the Board of the British Healthcare Business Intelligence Association since 2015 and was elected Chair in 2020. His career includes senior leadership roles at Novo Nordisk and Sanofi, as well as a secondment to NHS England during the COVID-19 response.